SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...
SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...
SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...
SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...
SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...
SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...
SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically...
Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...
SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...
Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.